Tools and Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand Convergence in Malaria?

PLoS Biology

Volumn 14, Issue 3, 2016, Pages

  Hemingway, Janet ^a   Shretta, Rima ^b   Wells, Timothy N C ^c   Bell, David ^d   Djimdé, Abdoulaye A ^e   Achee, Nicole ^f   Qi, Gao ^g  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Medicines for Malaria Venture   (Switzerland)

^d Global Good Fund and Intellectual Ventures Laboratory   (United States)

^e UNIVERSITY OF BAMAKO   (Mali)

^f UNIVERSITY OF NOTRE DAME   (United States)

^g JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORO 2 [4 (MORPHOLINOMETHYL)PHENYL] 4 [2 (1 PYRROLIDINYL)ETHYLAMINOMETHYL]QUINOLINE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISONE; CIPARGAMIN; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; ENDOPEROXIDE; FERROQUINE; FOSMIDOMYCIN; INSECTICIDE; MALARIA VACCINE; METHYLENE BLUE; OZ 439; PIPERAQUINE; PRIMAQUINE; PYRETHROID; SEVUPARIN; TAFENOQUINE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT;

AEDES; ANOPHELES; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BED NET; CROP PROTECTION; DISEASE ELIMINATION; DISEASE ERADICATION; DISEASE SURVEILLANCE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; INDOOR RESIDUAL SPRAYING; INSECTICIDE RESISTANCE; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; LOW DRUG DOSE; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MALARIA RAPID TEST; MASS SCREENING; NONHUMAN; PARASITE TRANSMISSION; PARASITEMIA; PLASMODIUM VIVAX MALARIA; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; SEASONAL VARIATION; SINGLE DRUG DOSE; VECTOR CONTROL; ANTIBIOTIC RESISTANCE; EPIDEMIOLOGICAL MONITORING; PUBLIC HEALTH SERVICE;

ANTIMALARIALS; DRUG RESISTANCE, MICROBIAL; EPIDEMIOLOGICAL MONITORING; HUMANS; INSECTICIDES; MALARIA; PUBLIC HEALTH PRACTICE;

EID: 84962157143     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1002380     Document Type: Article

References (41)

1. WHOWorld Malaria Report2014. Geneva, Switzerland: World Health Organization, 2014. http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/
2. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet. 2013;382(9908):1898–955. doi: 10.1016/S0140-6736(13)62105-424309475
3. Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ, et al. Malaria resurgence: a systematic review and assessment of its causes. Malar J. 2012;11:122. doi: 10.1186/1475-2875-11-12222531245
4. Surveillance Systems to Facilitate Malaria Elimination. UCSF Global Health Sciences Global Health Group, 2014. http://globalhealthsciences.ucsf.edu/sites/default/files/content/ghg/mei-surveillance-systems-to-facilitate.pdf
5. Cao J, Sturrock HJ, Cotter C, Zhou S, Zhou H, Liu Y, et al. Communicating and monitoring surveillance and response activities for malaria elimination: China's "1-3-7" strategy. PLoS Med. 2014;11(5):e1001642. doi: 10.1371/journal.pmed.100164224824170
6. Ohrt C, Roberts KW, Sturrock HJ, Wegbreit J, Lee BY, Gosling RD, Information Systems to Support Surveillance for Malaria Elimination. Am J Trop Med Hyg. 2015;93(1):145–152. doi: 10.4269/ajtmh.14-025726013378
7. Kelly GC, Tanner M, Vallely A, Clements A, Malaria elimination: moving forward with spatial decision support systems. Trends Parasitol. 2012;28(7):297–304. doi: 10.1016/j.pt.2012.04.00222607693
8. Graves PM, Gelband H, Garner P, Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev. 2015;2:CD008152. doi: 10.1002/14651858.CD008152.pub425693791
9. Baird K, Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. Pathog Glob Health. 2015;109(3):93–106. doi: 10.1179/2047773215Y.000000001625943156
10. Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN, Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187. doi: 10.1186/1475-2875-12-18723742293
11. The malERA Consultative Group on DrugsA research agenda for malaria eradication: drugs. PLoS Med. 2011;8(1):e1000402. doi: 10.1371/journal.pmed.100040221311580
12. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A. 2011;108(11):4400–5. doi: 10.1073/pnas.101576210821300861
13. The Safety and Effectiveness of Single Dose Primaquine as a P. falciparum Gametocytocide. WHO Malaria Policy Advisory Committee, 2012. http://www.who.int/entity/malaria/mpac/sep2012/primaquine_single_dose_pf_erg_meeting_report_aug2012.pdf?ua=1
14. White NJ, Qiao LG, Qi G, Luzzatto L, Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J. 2012;11:418. doi: 10.1186/1475-2875-11-41823237606
15. Ashley EA, Recht J, White NJ, Primaquine: the risks and the benefits. Malar J. 2014;13:418. doi: 10.1186/1475-2875-13-41825363455
16. Malaria Elimination Initiative. MEI Primaquine Roadmap Update. UCSF Global Health Group. http://globalhealthsciences.ucsf.edu/global-health-group
17. Rajapakse S, Rodrigo C, Fernando SD, Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2015;4:CD010458. doi: 10.1002/14651858.CD010458.pub225921416
18. Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in children. A field guide. WHO 2013. ISBN 978924 150473 7.
19. Global Portfolio of Antimalaria Medicines, 1Q 2015: Medicines for Malaria Venture; 2015. http://www.mmv.org/
20. Wells TN, van Huijsduijnen RH, Van Voorhis WC, Malaria medicines: a glass half full?Nat Rev Drug Discov. 2015;14(6):424–42. doi: 10.1038/nrd457326000721
21. Malaria Vaccine Technology Roadmap. Malaria Vaccine Funders Group, 2006. http://www.who.int/immunization/topics/malaria/malaria_vaccine_funders_group/en/
22. Malaria Vaccine Technology Roadmap. Malaria Vaccine Funders Group, 2013. http://www.who.int/immunization/topics/malaria/malaria_vaccine_funders_group/en/
23. Vaccines: a step change in malaria prevention?Lancet. 2015;385(9978):1591. doi: 10.1016/S0140-6736(15)60774-725943796
24. RTS S Clinical Trials PartnershipEfficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015.
25. Tran TM, Portugal S, Draper SJ, Crompton PD, Malaria Vaccines: Moving Forward After Encouraging First Steps. Curr Trop Med Rep. 2015;2(1):1–3. 25995985
26. Nikolaeva D, Draper SJ, Biswas S, Vandekerckhove S, D'Hooghe M, Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev Vaccines. 2015;14(5):653–80. doi: 10.1586/14760584.2015.99338325597923
27. WHO. Malaria Vaccine Rainbow Tables 2015. http://www.who.int/immunization/research/development/Rainbow_tables/en/
28. Toe KH, Jones CM, N'Fale S, Ismail HM, Dabire RK, Ranson H, Increased pyrethroid resistance in malaria vectors and decreased bed net effectiveness, Burkina Faso. Emerg Infect Dis. 2014;20(10):1691–6. doi: 10.3201/eid2010.14061925279965
29. Oxborough RM, Kitau J, Jones R, Feston E, Matowo J, Mosha FW, et al. Long-lasting control of Anopheles arabiensis by a single spray application of micro-encapsulated pirimiphos-methyl (Actellic(R) 300 CS). Malar J. 2014;13:37. doi: 10.1186/1475-2875-13-3724476070
30. Rowland M, Boko P, Odjo A, Asidi A, Akogbeto M, N'Guessan R, A new long-lasting indoor residual formulation of the organophosphate insecticide pirimiphos methyl for prolonged control of pyrethroid-resistant mosquitoes: an experimental hut trial in Benin. PLoS ONE. 2013;8(7):e69516. doi: 10.1371/journal.pone.006951623936033
31. Hemingway J, The role of vector control in stopping the transmission of malaria: threats and opportunities. Philos Trans R Soc Lond B Biol Sci. 2014;369(1645):20130431. doi: 10.1098/rstb.2013.043124821917
32. Killeen GF, Characterizing, controlling and eliminating residual malaria transmission. Malar J. 2014;13:330. doi: 10.1186/1475-2875-13-33025149656
33. Wilson AL, Chen-Hussey V, Logan JG, Lindsay SW, Are topical insect repellents effective against malaria in endemic populations? A systematic review and meta-analysis. Malar J. 2014;13:446. doi: 10.1186/1475-2875-13-44625413142
34. Burt A, Heritable strategies for controlling insect vectors of disease. Phil. Trans Roy Soc. B. doi: 10.1098/rstb.2013.0432
35. Moody A, Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 2002;15(1):66–78. 11781267
36. Smith Gueye C, Sanders KC, Galappaththy GN, Rundi C, Tobgay T, Sovannaroth S, et al. Active case detection for malaria elimination: a survey among Asia Pacific countries. Malar J. 2013;12:358. doi: 10.1186/1475-2875-12-35824103345
37. Sturrock HJ, Hsiang MS, Cohen JM, Smith DL, Greenhouse B, Bousema T, et al. Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Med. 2013;10(6):e1001467. doi: 10.1371/journal.pmed.100146723853551
38. Sturrock HJ, Novotny JM, Kunene S, Dlamini S, Zulu Z, Cohen JM, et al. Reactive case detection for malaria elimination: real-life experience from an ongoing program in Swaziland. PLoS ONE. 2013;8(5):e63830. doi: 10.1371/journal.pone.006383023700437
39. Hsiang MS, Hwang J, Tao AR, Liu Y, Bennett A, Shanks GD, et al. Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J. 2013;12:383. doi: 10.1186/1475-2875-12-38324175930
40. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J, Mass drug administration for malaria. Cochrane Database Syst Rev. 2013;12:CD008846. doi: 10.1002/14651858.CD008846.pub224318836
41. Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, et al. Review of Mass Drug Administration for Malaria and Its Operational Challenges. Am J Trop Med Hyg. 2015;93(1):125–34. doi: 10.4269/ajtmh.14-025426013371